<?xml version="1.0" encoding="iso-8859-1" standalone="no" ?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>PRO000000000000510009</messagenumb>
    <messagesenderidentifier>EMDSERONO</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125162603</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">CA-US-EMD Serono, Inc.-7188839</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20130125</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20130116</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20130116</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">CA-Merck KGaA-7188839</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <primarysource>
      <reporterfamilyname>Unknown</reporterfamilyname>
      <reportercountry>CA</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <senderorganization>US-EMD Serono, Inc.</senderorganization>
      <senderdepartment>US Product Surveillance and Quality Assurance</senderdepartment>
      <sendertitle>Dr</sendertitle>
      <sendergivename>Daryl</sendergivename>
      <senderfamilyname>Dawson</senderfamilyname>
      <senderstreetaddress>One Technology Place</senderstreetaddress>
      <sendercity>Rockland</sendercity>
      <senderstate>MA</senderstate>
      <senderpostcode>02370</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>781-681</sendertel>
      <sendertelextension>2564</sendertelextension>
      <sendertelcountrycode>+1</sendertelcountrycode>
      <senderfax>781-681</senderfax>
      <senderfaxextension>2961</senderfaxextension>
      <senderfaxcountrycode>+1</senderfaxcountrycode>
      <senderemailaddress>usps@emdserono.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>US-A-Food and Drug Administration</receiverorganization>
      <receiverdepartment>AERS</receiverdepartment>
      <receivertitle>Mr</receivertitle>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>CDER</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
      <receivercity>Rockville</receivercity>
      <receiverstate>MD</receiverstate>
      <receiverpostcode>20851</receiverpostcode>
      <receivercountrycode>US</receivercountrycode>
      <receivertel>3017709299</receivertel>
      <receivertelcountrycode>001</receivertelcountrycode>
      <receiverfax>3017706614</receiverfax>
      <receiverfaxcountrycode>001</receiverfaxcountrycode>
      <receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
    </receiver>
    <patient lang="en">
      <patientonsetage>39</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>52</patientweight>
      <patientheight>157</patientheight>
      <patientsex>2</patientsex>
      <reaction>
        <primarysourcereaction lang="en">DEPRESSED LEVEL OF CONSCIOUSNESS</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10012373</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10012373</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">APHASIA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10002948</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10002948</reactionmeddrapt>
        <termhighlighted>2</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">DYSPHAGIA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10013950</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10013950</reactionmeddrapt>
        <termhighlighted>2</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">HEART RATE INCREASED</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10019303</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10019303</reactionmeddrapt>
        <termhighlighted>2</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">MUSCLE SPASMS</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10028334</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10028334</reactionmeddrapt>
        <termhighlighted>2</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">MUSCULAR WEAKNESS</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10028372</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10028372</reactionmeddrapt>
        <termhighlighted>2</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">RESPIRATORY RATE INCREASED</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10038712</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10038712</reactionmeddrapt>
        <termhighlighted>2</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">PYREXIA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10037660</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10037660</reactionmeddrapt>
        <termhighlighted>2</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REBIF</medicinalproduct>
        <drugauthorizationnumb>103780</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugstructuredosagenumb>22</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugdosagetext lang="en">Kit</drugdosagetext>
        <drugdosageform lang="en">Injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
        <actiondrug>5</actiondrug>
        <activesubstance>
          <activesubstancename>INTERFERON BETA-1A</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10012373</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10012373</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10002948</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10002948</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10013950</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10013950</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10019303</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10019303</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10028334</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10028334</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10028372</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10028372</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10038712</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10038712</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10037660</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10037660</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical lang="en">This case report from a physician in Canada was received via Canadian Health Authority (000126054) at Merck Serono on 16 Jan 2013. 
A 39-year-old female patient experienced depressed level of consciousness, aphasia, dysphagia, heart rate increased, muscle spasms, muscular weakness, respiratory rate increased and pyrexia. 
The event depressed level of consciousness was assessed as medically significant by the Company.
The patient's relevant medical history and concomitants were not provided.
The patient received Rebif (interferon beta 1a) at a dose of 22 mcg subcutaneously once on an unspecified date for an unknown indication.
On an unspecified date, the patient experienced depressed level of consciousness, aphasia, dysphagia, heart rate increased, muscle spasms, muscular weakness, respiratory rate increased and pyrexia. As corrective measure, the  patient took Ativan (lorazepam) at a dosage of 1 mg sublingually.
As of 16 Jan 2013, action taken with Rebif therapy was not reported.
As of 16 Jan 2013, all the events had resolved.
The reporter did not provide any causality assessment.</narrativeincludeclinical>
        <sendercomment lang="en">Depressed level of consciousness [Depressed level of consciousness] in a 39-year-old female patient, an unspecified period of time after the first administration of Rebif for unknown indication. In addition, the patient experienced the following non serious events: aphasia [Aphasia], dysphagia [Dysphagia], heart rate increased [Heart rate increased], muscle spasms [Muscle spasms], muscular weakness [Muscular weakness], respiratory rate increased [Respiratory rate increased] and pyrexia [Pyrexia].
Temporal relationship: compatible. Latency: not assessable (Rebif start date and AEs onset dates were not reported). Dechallenge: not applicable (action taken with Rebif was not reported).
Causality by reporter (physician): not provided.
Causality by company: In absence of sufficient information to fully assess the case, depressed level of consciousness, aphasia, dysphagia, heart rate increased, muscle spasms, muscular weakness, respiratory rate increased have been assessed as causally related to Rebif. Pyrexia is assessed as related to Rebif.
Depressed level of consciousness, Aphasia, Dysphagia, Heart rate increased, Muscle spasms, Muscular weakness, and Respiratory rate increased are unlisted and Pyrexia is listed for Rebif as per reference safety information.

Follow-up information requested for Rebif therapy start date, frequency, indication, medical history, concomitant medication, action taken with Rebif and relevant investigations.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr>
